DBV Technologies Shares Rise 1.75% Amid Food‑Allergy Biotech Outlook
DBV Technologies SA trades near €1.70, rising 1.75% but lagging its €2.98 200‑day MA. A niche food‑allergy biopharma, it seeks market share through targeted immunotherapy. Stay alert for clinical & regulatory catalysts.
3 minutes to read